| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10587327 | Bioorganic & Medicinal Chemistry Letters | 2013 | 4 Pages |
Abstract
Due to the involvement of nitric oxide (NO) in numerous and diverse physiological processes, site-directed delivery of therapeutic NO in order to minimize unwanted side-effects is necessary. O2-(4-Nitrobenzyl) diazeniumdiolates are designed as substrates for Escherichia coli nitroreductase (NTR), an enzyme that is frequently used to facilitate directed delivery of cytotoxic species to cancers. O2-(4-Nitrobenzyl) diazeniumdiolates are found to be stable in aqueous buffer but are metabolized by NTR to produce NO. A cell viability assay revealed that cytotoxic effects of O2-(4-nitrobenzyl)1-(2-methylpiperidin-1-yl)diazen-1-ium-1,2-diolate (4b) towards two cancer cell lines is significantly enhanced in the presence of NTR suggesting the potential for use of this compound in nitric oxide-based directed prodrug therapy.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Kavita Sharma, Kundan Sengupta, Harinath Chakrapani,